Treatment with IV Antibiotics in an Outpatient POIC Shows Successful Outcomes and Cost Savings

BOSTON, MA (October 21, 2011) – A 3-year trend analysis was conducted of patients initiated on intravenous antibiotics (IVAB) in an Infectious Disease Physician Office Infusion Center (POIC) during the years 2008 – 2010 for a complicated skin and skin structure or osteomyelitis infection. Overall, 219 patients showed statistically consistent parameters including a clinical success rate of 90% or above for both diagnoses, an adverse event rate overall of 22%, with only 34% requiring any intervention, and a low catheter infection rate (0.34 per 1000 catheter days). Mean daily treatment costs were significantly lower (p<0.05 in all groups) in the POIC setting compared to hospital treatment costs for both indications during each of the 3 years and for the compiled data. Total cost savings realized during the 3 year period were over $1.5 million in just a single physician office, emphasizing that care can be safely and effectively provided in this setting without requiring a hospitalization.

This study was presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA). For a printed copy of this research poster study, please call 1.866.654.2451 or email [email protected].

About Healix, Inc.
Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

About IDSA
The 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) brought together physicians, scientists, and other health care professionals involved in research, patient care, public health, disease prevention, and education in the field of infectious diseases. The meeting showcased the latest news in the field of infectious diseases with emphasis on contemporary trends, including emerging infections, new diagnostic and therapeutic advances. IDSA 2011 took place October 20-23 at the Boston Exhibition and Convention Center in Boston, Massachusetts. For more information, visit www.idsa2011.org.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.